News &amp; Updates

Increased prostate volume in patients with low-grade prostate cancer on active surveillance appears to contribute to reduced risks of grade progression (GP) and receipt of definitive prostate cancer treatment, suggests a study.

HSCT after blinatumomab feasible in Asians with R/R B-ALL

In patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), allogeneic haematopoietic stem cell transplantation (HSCT) after blinatumomab is feasible and potentially safe, according to data from a nationwide registry in Japan.

1L blinatumomab + ponatinib improves fatigue & HRQoL in adults with Ph+ ALL

First-line (1L) blinatumomab + ponatinib improves patient-reported outcomes (PROs), including fatigue and health-related quality of life (HRQoL), vs imatinib + chemotherapy in adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia (ALL), results of the phase III GIMEMA ALL2820 trial have shown.

Blinatumomab improves 4-year survival in infants with KMT2A-rearranged ALL

Infants with KMT2A-rearranged acute lymphoblastic leukaemia (ALL) – a dire disease with poor prognosis despite treatment intensification under the latest protocols – are found to have improved 4-year disease-free survival (DFS) and overall survival (OS) with the addition of blinatumomab to standard chemotherapy.

Replacing 1L high-dose chemo with blinatumomab improves outcomes in paediatric high-risk B-ALL

Replacing two cycles of highly toxic, high-dose combination chemotherapy with two cycles of blinatumomab as first-line (1L) treatment significantly improves outcomes including 4-year event-free survival (EFS) and reduces adverse events (AEs) in paediatric patients with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), results of the phase III AIEOP-BFM 2017 trial have shown.

EV-induced cutaneous adverse events signal good prognosis in advanced urothelial cancer

29 Sep 2026

In patients with locally advanced or metastatic urothelial cancer, enfortumab vedotin (EV)-induced cutaneous adverse events (cAEs) are associated with improved survival outcomes, according to a retrospective study.

29 Sep 2026

Letermovir flops in lessening medication regimen complexity in allo-HCT recipients

28 Sep 2026 by

Letermovir prophylaxis falls short of reducing medication regimen complexity index (MRCI) over time in patients who underwent allogeneic haematopoietic stem cell transplantation (allo-HCT), according to a study.

Drug therapy problems prevalent in ovarian cancer patients

Patients with ovarian cancer are no strangers to several drug therapy problems (DTPs), particularly adverse drug reactions, suggests a study.

Use of statins after CRC treatment unlikely to confer large survival benefit

The survival benefit associated with the use of statins in adults treated for colorectal cancer (CRC) is only modest at best, according to a target trial emulation.